Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia.
Author supplied keywords
Cite
CITATION STYLE
Foss, F. M., Rubinowitz, A., Landry, M. L., Isufi, I., Gowda, L., Seropian, S., … Shenoi, S. V. (2020, November 1). Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma, Myeloma and Leukemia. Elsevier Inc. https://doi.org/10.1016/j.clml.2020.06.014
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
